Arbutus Biopharma Corporation (NASDAQ:ABUS) insider Michael J. Sofia sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total transaction of $111,000.00. Following the completion of the sale, the insider now owns 1,563,403 shares of the company’s stock, valued at approximately $5,784,591.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Arbutus Biopharma Corporation (ABUS) traded down 2.70% on Thursday, hitting $3.60. 28,173 shares of the stock traded hands. Arbutus Biopharma Corporation has a 52 week low of $2.35 and a 52 week high of $4.04. The firm’s 50 day moving average is $3.67 and its 200 day moving average is $3.30. The firm’s market capitalization is $198.09 million.

TRADEMARK VIOLATION WARNING: “Insider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 30,000 Shares of Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/17/insider-selling-arbutus-biopharma-corporation-abus-insider-sells-30000-shares-of-stock.html.

A number of equities research analysts have issued reports on ABUS shares. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma Corporation in a research report on Monday, August 7th. Ladenburg Thalmann Financial Services started coverage on shares of Arbutus Biopharma Corporation in a research report on Friday, June 2nd. They issued a “buy” rating and a $32.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 10th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Arbutus Biopharma Corporation currently has an average rating of “Buy” and a consensus price target of $11.65.

Several hedge funds have recently made changes to their positions in ABUS. Bank of Montreal Can raised its stake in shares of Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock worth $3,147,000 after buying an additional 16,535 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Arbutus Biopharma Corporation during the second quarter worth approximately $478,000. Renaissance Technologies LLC raised its stake in shares of Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 110,499 shares in the last quarter. OxFORD Asset Management LLP raised its stake in shares of Arbutus Biopharma Corporation by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 39,436 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Arbutus Biopharma Corporation by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 2,035 shares in the last quarter. 66.49% of the stock is currently owned by institutional investors and hedge funds.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.